Perspective Therapeutics (CATX) Accumulated Expenses (2016 - 2025)
Perspective Therapeutics (CATX) has disclosed Accumulated Expenses for 15 consecutive years, with $7.5 million as the latest value for Q4 2025.
- Quarterly Accumulated Expenses rose 36.71% to $7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, up 36.71% year-over-year, with the annual reading at $7.5 million for FY2025, 36.71% up from the prior year.
- Accumulated Expenses hit $7.5 million in Q4 2025 for Perspective Therapeutics, up from $6.7 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $7.5 million in Q4 2025 to a low of $240000.0 in Q1 2021.
- Historically, Accumulated Expenses has averaged $2.2 million across 5 years, with a median of $684000.0 in 2023.
- Biggest five-year swings in Accumulated Expenses: dropped 2.32% in 2022 and later soared 1158.95% in 2023.
- Year by year, Accumulated Expenses stood at $259000.0 in 2021, then rose by 10.04% to $285000.0 in 2022, then skyrocketed by 1158.95% to $3.6 million in 2023, then surged by 52.68% to $5.5 million in 2024, then soared by 36.71% to $7.5 million in 2025.
- Business Quant data shows Accumulated Expenses for CATX at $7.5 million in Q4 2025, $6.7 million in Q3 2025, and $5.0 million in Q2 2025.